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The discovery that stem cells isolated from different organs have the ability to differentiate into mature beating cardiomyocytes has
fostered considerable interest in developing cellular regenerative therapies to treat cardiac diseases associated with the loss of viable
myocardium. Clinical studies evaluating the potential of stem cells (from heart, blood, bone marrow, skeletal muscle, and fat) to
regenerate themyocardium and improve its functional status indicated that although themethod appeared generally safe, its overall
efficacy has remained modest. Several issues raised by these studies were notably related to the nature and number of injected cells,
as well as the route and timing of their administration, to cite only a few. Besides the direct administration of cardiac precursor
cells, a distinct approach to cardiac regeneration could be based upon the stimulation of the heart’s natural ability to regenerate,
using pharmacological approaches. Indeed, differentiation and/or proliferation of cardiac precursor cells is controlled by various
endogenous mediators, such as growth factors and cytokines, which could thus be used as pharmacological agents to promote
regeneration. To illustrate such approach, we present recent results showing that the exogenous administration of the natriuretic
peptide BNP triggers “endogenous” cardiac regeneration, following experimental myocardial infarction.
1. Introduction
Cardiovascular diseases (CVDs) account for 30% of all deaths
worldwide, which represented 17.3 million fatalities in 2008
(World Health Organization, Fact sheet number 317), among
which 13.5 million (80%) were related to the consequences of
coronary heart diseases (CHDs). This number is expected to
rise steadily, with an estimated 23.3 million deaths in 2030.
The identified causes of this “epidemics” involve a sedentary
life of style, an unhealthy diet, as well as the use of tobacco
and/or alcohol consumption [1, 2]. All favor the emergence of
obesity, diabetes, and/or hypertension which are risk factors
for CHDs.
Many efficient therapies have been developed to treat
CVDs over the past 30 years, including various reperfu-
sion strategies of occluded coronary vessels, antiplatelet and
anticoagulant agents to prevent/treat coronary thrombo-
sis, beta-blocking drugs, or angiotensin-converting enzyme
inhibitors, to name only a few [3]. However, despite the
identification of risk factors and the improvements in therapy,
the morbidity and mortality associated with CHDs remain
unacceptably high. Amajor reason for it is that CHDs induce
the loss of a given amount of contractile myocardium, with
unavoidable consequences on the functional activity of the
heart. Indeed, themammalian heart has long been considered
a postmitotic organ with no capacity to regenerate [4],
which is in striking contrast with certain lower vertebrates
(zebrafish, urodeles), which have a high cardiac regeneration
rate.The various treatments aimed to delay the onset of heart
failure or to limit the consequences of CVDs, do not have
the ability to replace the damaged cardiac cells, especially
the necrotic and/or apoptotic cardiomyocytes [5], and thus
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cannot properly “heal” the injured heart.This view has begun
to change dramatically with the discovery that the adult
heart displays some capacity to regenerate after damage and,
hence, that manipulating such regenerative capacity might
have therapeutic potential. These emerging concepts will be
here concisely reviewed.
2. Regenerative Capacities of the Adult
Mammalian Heart
In the last decade, intensive research in the cardiovascular
field has allowed a more precise understanding of the cel-
lular and molecular mechanisms governing cardiomyocyte
differentiation and proliferation during physiological growth,
ageing, and pathophysiological conditions. A milestone
observation was the demonstration that cardiac regeneration
represents a physiological process occurring during ageing
in normal conditions [6]. Although the proportion of newly
formed cardiomyocytes is currently debated, the fact that
new cardiomyocytes are generated in human hearts during
physiological ageing and after heart injuries is now well
admitted [6–8]. Differentmechanisms have been identified to
account for the de novo generation of cardiomyocytes in the
adult heart. These mechanisms, detailed below, include the
proliferation of the preexisting mature cardiomyocytes with
or without dedifferentiation, the differentiation of endoge-
nous precursor cells, and the differentiation of exogenous
infiltrating cells (for review see [9]).
2.1. Proliferation of Mature Cardiomyocytes. Although car-
diomyocytes in mammals demonstrate proliferative capaci-
ties during fetal development, it has been commonly admit-
ted that after birth, cardiomyocytes cannot reenter the cell
cycle, as DNA replication occurs without cytokinesis or
karyokinesis [10]. This assumption was first challenged by
the Sadek laboratory, who demonstrated that mouse car-
diomyocytes can proliferate after partial surgical resection
of the heart at birth [11]. In this mouse model, cardiomy-
ocyte proliferation led to the replacement of the resected
tissue and the inhibition of fibrosis. Notwithstanding this
obvious regenerative process, the capacity of murine car-
diomyocytes to proliferate was lost after 7 days of age.
Further evidence of cardiomyocyte ability to proliferate
came from the Lee laboratory, who recently proposed that
preexisting cardiomyocytes represent the main source of
newly formed cardiomyocytes during ageing, as well as
followingmyocardial infarction (MI) [12].However, although
cardiomyocyte proliferation occurs life-long, this process
is seldom in the mouse heart after the first month of life
[13].
The mechanisms by which cardiomyocytes are able to
proliferate are notwell established. In zebrafish hearts,mature
cardiomyocytes have to dedifferentiate before proliferating
[14]. During this dedifferentiation, cardiomyocytes reduce
their sarcomere structure (they become smaller and round)
and reexpress the alpha skeletal actin (𝛼-ska) protein as well
as cardiac progenitor cell markers, such as Nkx2.5 and c-kit.
They downregulate the expression of prototypical markers of
mature cardiomyocytes, such as Troponin I and 𝛼-myosin
heavy chain (𝛼-MHC). Their new structure and phenotype
facilitate their reentry into the cell cycle. This process has
also been observed in vitro in cardiomyocyte isolated from
rat hearts [15]. However, whether this process occurs in
vivo in mammal hearts is under debate. Dedifferentiated
cardiomyocytes have been detected in the hearts of infarcted
sheep hearts or in pressure-and-volume overloaded rabbit
hearts [16, 17]. In human hearts after idiopathic dilated car-
diomyopathy, infarction or atrial fibrillation dedifferentiated
cardiomyocytes were also detected [18, 19]. The presence of
these cells has been shown to be dependant at least in part by
Oncostatin M [20]. However the results published until now
did not demonstrate a direct link between the cardiomyocyte
dedifferentiation and the proliferation. In other words, the
results demonstrating that dedifferentiated cardiomyocytes
proliferate in vivo are lacking.
However, stimulation of the cardiomyocyte proliferation
appears as a new therapeutical strategy to increase cardiac
regeneration especially in pathophysiological conditions.
Several factors have been identified to be able to induce
cardiomyocytes to reenter the cell cycle: Neuregulin 1 and
its ERBB2 receptor [21–24], Periostin [25], the fibroblast
growth factor-1 [26, 27], or also the stromal cell-derived
factor 1𝛼 [28]. The use of miRNAs is also investigated and
demonstrated that hsa-miR-590 and hsa-miR-199a were able
to stimulate cardiomyocyte proliferation [29]. Interestingly,
new results published by Sadek laboratory demonstrated that
hypoxia is a crucial factor able to stimulate cardiomyocyte
proliferation [30]. The authors identified in adult mouse
hearts a small population of proliferating cardiomyocytes
expressingHif-1𝛼 and able to give rise to new cardiomyocytes
(at a rate of 0.3–1% per year) during physiological ageing.
Thus, these results could explain why in neonatal hearts
(relatively more hypoxic than adult hearts) cardiomyocytes
proliferate. Thus, the oxygen postnatal environment which
has been shown to lead to DNA damage response [31],
appears as a major regulator of cardiomyocyte proliferation.
However, the regulation of other genes such as p21 or the
transcription factor Meis1 [32, 33] or the mechanical loading
of the hearts [34] could also contribute to the arrest of
cardiomyocyte proliferation in postnatal hearts.
2.2. Differentiation of Endogenous Precursor Cells. Cardiac
precursor cells (CPCs), which have the capacity to differ-
entiate into mature functional cardiomyocytes, exist in the
heart itself. The characterization of these cells remains a
difficult task, due to the lack of a defined, highly specific
marker.Thus the association of several markers is required to
identify cardiovascular progenitor and cardiac precursor cells
[35, 36] (Figure 1). Early cardiogenic precursors originate
from mesoderm and are identified as expressing the c-kit
protein [37–39] (a cellular cytokine receptor initially found
at the surface of hematopoietic progenitor cells), the vascular
endothelial growth factor (VEGF) receptor 2 protein (Flk-
1) [40], and the nuclear transcription factor islet-1 [35, 41,
42]. These relative undifferentiated cells give rise to multi-
potent cardiovascular progenitors which express the nuclear
transcription factor Nkx2.5 [43, 44] together with the islet-
1, Flk-1, and c-kit proteins. These progenitors differentiate
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Figure 1: Cardiovascular cell lineage. Schematic representation depicting the origin of cardiomyocytes and endothelial and smooth muscle
cells, as well as the conduction system. Several proteins are associated with the different stage of differentiation of the cardiac cells: islet-1,
Flk-1, and c-kit are expressed at an undifferentiated stage, whereas the expression of Nkx2.5 and Sca-1 identifies more differentiated cardiac
precursor cells.
into vascular precursors expressing the endothelial markers
CD34 and CD31 or into cardiac precursor cells expressing
notably Nkx2.5, GATA-4, Mef2c, and the stem cell antigen-
1 (Sca-1) proteins [42, 45–47]. CPCs can differentiate into
cells of the conduction system, into smooth muscle cells,
and into cardiomyoblasts expressing Hopx [48]. Hopx+ cells
give only rise to cardiac myocytes (immature and mature
cardiomyocytes).
The participation of the endogenous CPCs to heart
regeneration in physiological conditions is controversial [8,
12]. Under pathological conditions, it is now well estab-
lished that CPCs can differentiate into cardiomyocytes when
they were activated with different stimuli, such as FGF-2,
thymosin 𝛽4, prostaglandin E2, human stem cell factor, or
also stromal-cell derived factor 1 (SDF1) [8, 49–53]. However,
such involvement seems to be limited in time, as indicated
by Hsueh and coworkers who reported that CPC differen-
tiation into cardiomyocytes started at day 7 after MI but
saturated on day 10 [51]. Interestingly, in senescent heart,
CPCs are quiescent because of lack of stimulation but they
can be re-activated by stem cell factor [39]. This suggests
that, even in old hearts, activation of endogenous CPCs
could be used as a therapeutical way to increase cardiac
regeneration.
Among the “direct” activation of CPCs with several
factors, the microenvironment of the CPCs can also be
modified to increase their potency to participate into heart
regeneration. Thus, their migration capacity which is depen-
dent on the SDF1 secreted by the damaged myocardium and
its CXCR 4 receptor (expressed by CPCs) can be modulated
[54]. The group of Wang induced overexpression of SDF1 by
the cardiomyocytes, which led to increased mobilization of
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CPCs [55]. SDF1 has also been shown to activate the endoge-
nous cardioblasts in adult hearts after myocardial infarction
[53].
2.3. Role of Infiltrating Cells from Extracardiac Origin.
Although the role of infiltrating cells is not yet well defined,
inhibition of certain aspects of inflammation is detrimen-
tal to cardiac repair after myocardial infarction [56–58],
pointing to some role of infiltrating cells in the regenerative
process. In this respect, evidence has accumulated that
monocytes/macrophages are key players in this scenario [57],
a concept notably supported by the increased mortality of
MI in mice following transient macrophage depletion [58].
Two different subsets ofmonocytes originating from the bone
marrow, with different, yet complementary functions, are
mobilized in the heart after MI: the CD11bhigh/Ly6Chigh sub-
set infiltrates the heart 1–3 days after MI, exhibits phagocytic,
proteolytic, and inflammatory functions, and represents 75%
of the monocytes in the infarcted hearts at this stage (of note,
Ly6Chigh monocytes originating from the spleen have also be
detected in the MI site [59]); the CD11bhigh/Ly-6Clow subset
colonizes the heart from day 4 to day 7 and produces less
inflammatory mediators but expresses vascular-endothelial
growth factor (VEGF), thus promoting angiogenesis [56].
Thus whether a paracrine effect of these cells is now
evident (for review see [60]), their ability to differentiate
into mature cardiomyocytes remains controversial. Indeed,
the differentiation into cardiomyocytes of cells isolated from
the bone marrow (BMCs) or the blood was first demon-
strated [61–65] and then challenged, with the suggestion that
these cells might rather fuse with the native cells instead
of differentiating [64, 66, 67]. Finally, now several reports
demonstrated that both processes, actual differentiation and
fusion, coexist [68, 69]. This was, for example, demonstrated
for human circulating CD14+ monocytes infiltrating the
infarcted myocardium [70] and recently for hematopoietic
cells which are able to “fuse” with cardiomyocytes and/or
“transdifferentiate” into cardiomyocytes.Whatever the fate of
the circulating cells in the heart, numerous factors secreted by
these cells have been identified, such as vascular endothelial
growth factor (VEGF), insulin growth factor (IGF-1), growth
hormone (GH), or hepatocyte growth factor (HGF). These
factors promote angiogenesis and atherogenesis but can also
stimulate endogenous CPC proliferation and differentiation
[71].
3. Therapeutic Issues in Cardiac Regeneration
3.1. Cardiac Cell Therapies. The idea leading to the devel-
opment of cellular therapy in damaged heart is to replace
the large amount of cardiomyocytes which died after heart
injuries. Thus, cellular therapies, consisting in injecting “car-
diomyocyte precursor cells” from various sources into the
injured hearts, have been evaluated as the first option in this
novel therapeutic paradigm.
Three categories of stem cells could be used: embryonic,
adult, and induced pluripotent stem cells (iPSCs). It is
important to mention here that, due primarily to ethical
issues, only one clinical trial performed so far has used
cardiac progenitors derived from human embryonic cells
(hESCs) [72]. However, the use of these cells is promising as
they regenerate nonhuman primate hearts [73]. In the same
way, iPSCs [74] were not yet tested in patients. Furthermore,
the discussion is open concerning the use of stem cells from
umbilical cord stroma [75].
Thus almost all clinical trials were performed with adult
stem cells (Figure 2).The choice of the type of adult precursor
cells to inject must be based on 3 main criteria. (1) They
should be easily isolated from patients (“autologous cells”)
or from healthy donors (“allogeneic cells”). (2) They should
be expandable in large number (>100 millions in the case of
bone marrow cells), implying that the cells should be kept in
an undifferentiated state in vitro, to allow high proliferative
capacity. (3) They should have the ability to differentiate into
mature cardiomyocytes.
Two types of cells fulfilling these criteria have been used
in clinical trials: cells isolated from the bone marrow, blood,
skeletal muscle, or fat, referred to as “exogenous” precursor
cells, and cells isolated from the heart itself (from atrial
biopsies) referred to as “endogenous” precursor cells.
3.1.1. The “Exogenous” Precursor Cells. The easiest precursor
cells to isolate are obtained from the blood or the bone mar-
row (BMCs).Thus, a vast majority of clinical trials performed
so far used BMCs, either unselected, or sorted according to
some markers of undifferentiated BMCs (CD133+ or CD34+
enriched BMCs). Mesenchymal stem cells (MSCs), obtained
by specific culture processing of the BMCs, have been
frequently used as well and indeed are generally presented as
the “most effective cells” which can be injected [76].
The results obtained using BMC injection (usually via an
intracoronary or a percutaneous transendocardial injection)
have been generally disappointing, as summarized in recent
extensive reviews [76, 77]. A meta-analysis of 13 randomized
trials of unsorted BMC injection in patients with acute MI
concluded that BMCs did not prevent the remodeling process
[78]. The REPAIR-AMI trial, which is a multicenter double-
blind trial of the intracoronary injection of BMCs after acute
MI, reported a 5.5% increase of left ventricular ejection
fraction in post-MI patients at 6 months [79]. However,
18 months after cell injection, no significant difference in
left ventricular ejection fraction was detected between cell
and placebo injected patients included in the REPAIR-
AMI trial. Similarly, BMC injection in patients after ST-
elevation myocardial infarction (BOOST trial) led to 6%
increase of the left ventricular ejection fraction 6 months
after cell injection (𝑃 = 0.003) but only to 2.8% at 18
months (𝑃 = 0.27) [80]. Recently a meta-analysis using
the individual data of the patients involved in 12 random-
ized trials concluded that intracoronary injection of bone
marrow cells after MI provides no benefit for the patients
[81].
However, with respect to CD133+ enriched BMCs and
MSCs, their administration after acute MI did result in mod-
erate improvements of cardiac parameters when compared
to control patients with in some cases a small reduction of
the absolute scar size [82–84]. Furthermore, patients injected
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Figure 2: Current state of stem cell therapy for acute myocardial infarction in clinical trials. The optimal cell population for cardiac
regenerative cell therapies requires autologous or allogeneic origin, rapid ex vivo expansion, and cardiac commitment including differentiation
to cardiomyocytes. Numerous clinical trials have been undertaken with moderate results (for reviews see [8, 77, 172–174]). ADRC: adipose-
derived stem cells; BMC: bone marrow cells; CDC: cardiosphere-derived cells; CM: cardiomyocytes; EPC: endothelial progenitor cells; HSC:
hematopoietic stem cells; LVEF: left ventricular ejection fraction; MSC: mesenchymal stem cells; SC: stem cells.
with a larger percentage of CD31+ cells among their BMCs,
demonstrated a greater reduction of infarct size than patients
injected with smaller percentage of CD31+ [85]. This clearly
demonstrates that the nature of the cells which are injected is
crucial for the outcome of the therapy.
Cells other than BMCs have been used in some clinical
trials. In the MAGIC trial, patients undergoing coronary
bypass surgery for previous MI and severe left ventricular
dysfunction were injected with skeletal myoblasts (cultured
from a muscle biopsy) within the myocardial scar. Myoblast
transfer did not improve LV function in comparison to
control patients and was associated with early postoperative
arrhythmias [86]. Finally, two recent clinical studies used
adipose tissue-derived regenerative cells (ADRCs, isolated
from liposuction aspirates), administered to patients with
acute MI [87] or severe chronic ischemic cardiomyopathy
[88]. Results of these studies are encouraging, as ADRCswere
associatedwith a 50% reduction ofmyocardial scar formation
post-MI and a preserved ventricular function in patients with
ischemic cardiomyopathy. Additional studies are needed to
confirm these preliminary results.
3.1.2. The “Endogenous” Precursor Cells. Precursor cells do
exist within the heart, but their identification has been
made difficult by the lack of a highly specific marker. Cells
expressing the c-kit have been isolated from the heart,
induced to proliferate in vitro and reinjected into patients
as cardiac precursor cells from “autologous cardiac origin.”
The first clinical trials with autologous CPCs used c-kit+
cells obtained from atrial biopsies (SCIPIO study) or from
cardiospheres (self-assemblingmulticellular clusters contain-
ing various progenitor cells) obtained from right ventricular
tissue (CADUCEUS study). The cells have been injected
into the coronary circulation of a small number of patients
with ischemic cardiomyopathy or acute MI [89, 90]. These
trials first indicated the safety of the CPCs administration
procedure. Initial results, obtained 6 months after injection,
reported a reduction in the myocardial scar mass, although
an improvement in cardiac function was only reported in the
SCIPIO trial (but concerns regarding scientific integrity of the
latter study have been recently raised [91]). At 1-year follow-
up, the CADUCEUS study confirmed the early findings,
showing decreased scar size, increased viable myocardium,
and improved regional function of the infarctedmyocardium
[92].
3.1.3. Autologous or Allogeneic Cells? The use of “autologous”
injected cells (i.e., cells isolated from the patient itself and
reinjected) was first recommended to avoid the immunologi-
cal problems of rejection. However, their use is limited by the
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fact that they are not immediately available in high number
and that their isolation could be difficult in critically affected
patients. Furthermore, their immunogenicity is higher than
expected. Indeed, their isolation and reinjection, their long-
term culture in several culture media (for the mesenchymal
stem cells isolated from the bone marrow, see review [93]),
and their genetic modification or their epigenetic reprogram-
ming (for the iPSCs see [94, 95]) can increase the expression
on their cell surfaces of themajor histocompatibility complex
(MHC in animals or HLA in humans) classes I or II antigens.
These “autologous” cells could be thus rejected after their
reinjection and this could explain why in human hearts
the long-term survival of injected BMCs is very low: only
2–5% of the injected autologous BMCs are still present in
the heart a few hours after administration [96], and among
these surviving cells, only a few actually become correctly
integrated cardiomyocytes. Thus, the amount of injected
cells which will eventually integrate into the tissue is not
sufficient to improve cardiac function.These results highlight
the “paracrine” activity of the injected cells which clearly
stimulates the “endogenous” cardiac cells, promotes their
proliferation and differentiation, or stimulates other repair
mechanisms, such as angiogenesis [97, 98].
Thus, if the injected cells can survive long enough to
secrete factors able to stimulate the “endogenous” capacity
of the heart to regenerate, allogeneic cell therapy can also be
considered as a valid option to induce cardiac regeneration.
Therefore, injection of allogeneicMSCs in infarcted rat hearts
[99, 100], dog hearts [101], or pig hearts [102] is safe and
improves heart function as well as injection of “autologous”
MSCs. Interestingly, human cardioblasts originating from the
differentiation of allogeneic MSCs were transplanted into
a patient developing a cardiomyopathy and demonstrated
positive therapeutical effect for more than 2 years [103]. This
is also true for cardiosphere-derived cells (CDCs). Indeed,
the efficiency of “allogeneic” CDC injection in patients after
myocardial infarction is being evaluated in the ALLSTAR
trial and will be compared to this obtained by injection of
“autologous” CDCs (evaluated in the CADUCEUS trial [90,
104]). Preclinical results obtained in rats and pigs suggested
that injection of allogeneic CDCs was safe, induced no
immunological reaction, and acted via the samemechanisms
than the autologous CDC injection [105].
The injection of allogeneic cells presents several advan-
tages: these cells could be isolated from “healthy” donors,
stocked in “biobanks” in large number, thus immedi-
ately available in high numbers for patients. However, the
immunogenicity of these cells remains amajor hurdle to their
use in regenerative medicine. Indeed, if the human precursor
cells (especially the MSCs) and the human embryonic stem
cells express constitutively the HLA proteins at low levels,
when stimulated with interferon gamma or fibroblast growth
factor 2 (FGF-2), both cell types increased HLA protein
expressions, which render these cells able to be rejected
rapidly on transplantation [106–110]. That is why currently
many researches are aimed at understanding how blunting
host immune responses to injected cells. This concerns
the development of strategies limiting, for example, the
host immune response (by immunosuppressive drugs, by
tolerogenic cell therapies, or also by injection of mono-
clonal antibodies neutralizing the host immune cells). The
immunogenicity of the injected cells can also be modified by
modulating the site of injection or the way of cell delivering
(some biomaterials can escape from host immune reactivity)
(for review see [111, 112]).
3.1.4. Important Conclusions Drawn from Cellular Therapies.
To sum up, clinical trials evaluating cellular therapies based
on “cardiomyocyte precursor cells” fromvarious sources have
not been as successful as expected to repair the injured heart.
As a matter of fact, all stem cells used in cell therapies,
such as BMCs, mesenchymal or adipose tissue-derived stem
cells, display important cytokine secretion. This “paracrine”
activity of the injected cells seems to be responsible for the
positive effects observed in injured hearts after cell injections.
Indeed, secreted factors stimulate the “endogenous” cardiac
cells and thus promote their proliferation, differentiation,
or other repair mechanisms, such as angiogenesis [97, 98].
Thus, the differentiation of the injected cells into functional
cardiomyocytes integrated to the injured hearts seems to
contribute only minimally to heart regeneration.
Improving the yield of incorporation/differentiation of
injected cells and stimulating growth of endogenous cardiac
cells to promote heart regeneration open the way to a new
therapeutic paradigm based on a pharmacological stand-
point. The fact that spontaneous differentiation (although
at very low rate) of endogenous CPCs occurs during life
demonstrates that these cells are functional but need to
be stimulated [6, 7]. Future regenerative therapies should
therefore capitalize on this feature and propose novel phar-
macological strategies to stimulate the proliferation and
differentiation of endogenous precursor cells.
3.2. Pharmacological Therapies to Promote Cell Regeneration
3.2.1. The Complex Micorenvironment of Niches Containing
CPCs. CPCs have been shown to be more abundant in the
atria, in the heart’s apex, and in the epicardium [113, 114],
where they are located within specialized microdomains
termed niches. The niches also contain differentiated cells,
such as cardiomyocytes, fibroblasts, or telocytes, which con-
trol the activation state of the CPCs via physical interactions
(through cell surface receptor and adhesion molecules such
as Notch-1 and integrins) or via chemical, paracrine activity
(such as the secretion of cytokines and growth factors)
[115].
Whereas at the resting state, CPCs in the niches are kept
undifferentiated and quiescent, they become activated to pro-
liferate and differentiate into vascular cells or cardiomyocytes
followingmyocardial injury, especiallymyocardial infarction.
In such conditions, the hypoxic microenvironment, as well
as molecules released by dying cardiomyocytes, for example,
HMGB-1, plays key roles in the activation of CPCs [39,
116, 117]. Furthermore, growing evidence also indicates that
infiltrating inflammatory cells recruited within the infarcted
hearts promote CPC activation within the niches by releasing
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a wealth of factors, including growth factors (e.g., FGF-2,
VEGF), prostaglandins, and cytokines (e.g., IL-10) [49, 51, 71,
76, 118] (see also Section 2.3).
3.2.2. Paracrine Activation of CPCs after Myocardial Infarc-
tion: A Role for the Brain Natriuretic Peptide? Thus, it appears
evident for us that the identification of a factor able to increase
the proliferation and differentiation of the “endogenous” car-
diac precursor cells could be a key point in the development
of cellular therapies aimed to regenerate injured hearts. That
is why we are interested in the brain natriuretic peptide
(BNP).
BNP is a cardiac hormone which belongs to the natri-
uretic peptide family, the othermembers of which include the
atrial natriuretic peptide (ANP) secreted by the cardiac atria
and the C-type related natriuretic peptide (CNP) secreted
by the brain, bone, and vascular endothelial cells. BNP
was first discovered in the bovine brain but it is now well
established that the main source of BNP in the body is
the heart, especially the ventricles [119]. BNP binds to two
distinct guanylyl cyclase receptors, denotedNPR-A andNPR-
B, promoting the intracellular generation of cyclic GMP
(cGMP) [120]. The accumulation of cGMP in the cytoplasm
activates protein kinase G (PKG) and the phosphodiesterases
2, 3, and 5 to elicit downstream signaling [120].
3.2.3. BNP Biosynthesis and Secretion. BNP is a polypeptide
of 32 amino acids (32 aa) in humans and pigs and 45 aa in
mice and rats. It is processed from a preprohormone of 132-
aa, posttranslationally modified into a 108-aa prohormone
termed proBNP. The latter is enzymatically cleaved by two
convertases, namely, corin and/or furin, resulting in an
inactive 76-residue amino-terminal fragment (NT-proBNP)
and an active 32-aa C-terminal fragment (BNP). Plasma
BNP and NT-proBNP can be detected in healthy people,
as well as uncleaved proBNP and O-glycosylated proBNP,
which are both biologically inactive [121]. Plasma BNP levels
increase in patients with various forms of heart failure and
are therefore used as a helpful clinical biomarker for the
diagnosis and follow-up of cardiac dysfunction [122]. It is
here important to mention that recent studies indicated that
plasma BNP measured during chronic heart failure rather
consists of the biologically inactive forms proBNP and O-
glycosylated proBNP [121, 123, 124]. These results have raised
the interesting question that heart failure might be in fact
associated with a deficit of biologically active BNP [124].
BNP is primarily secreted by ventricular cardiomyocytes
upon excessive stretch, increased transmural pressure, or
direct injury (see also Figure 3(b) in neonatal hearts). Cardiac
fibroblasts and endothelial cells can also secrete BNP, and, fol-
lowing MI, infiltrating immune cells (including neutrophils,
T cells, andmacrophages)may represent an additional source
of BNP [125]. Interestingly, immature cells such as embryonic
stem cells or also satellite cells are also able to secrete BNP
[126, 127].
3.2.4. Role of BNP in the Heart. Whereas the effects of
BNP on the regulation of natriuresis, diuresis, and vascular
tone are well documented, there remains an important gap
of knowledge regarding the proper actions of BNP on the
heart itself [119, 128]. In the adult, the rapid release of
BNP by the heart might represent an important compen-
satory protective mechanism in various cardiac pathologies.
In support of this assumption, it has been reported that
treatment with exogenous BNP facilitated the recovery of
cardiac function and improved preservation of cardiac tissue
in animal models of MI. Possible mechanisms included the
inhibition of cardiomyocyte apoptosis, as well as reduction of
hypertrophy and fibrosis [129–134]. BNP may also modulate
the immune response to cardiac injury and thereby serve to
avert excessive or deregulated inflammation in this setting.
Several studies performed in vitro indicated that BNP can
inhibit monocyte chemotaxis [135], deplete the number of
monocytes, B lymphocytes, and NK cells in cultured human
peripheral blood mononuclear cells [136], and regulate the
production of a wealth of inflammatory molecules by human
macrophages [137, 138]. In vivo, a study using transgenicmice
overexpressing BNP reported increased cardiac neutrophil
infiltration and MMP-9 expression after MI in transgenic
animals, pointing to a key role of BNP in the processes of
matrix remodeling and wound healing in this setting [138].
Several studies also pointed out a role of BNP in
cardiac embryogenesis. High levels of BNP are measured
during midgestation in embryonic hearts, and peaks of BNP
secretion correlate with several important steps of cardiac
development [139, 140]. In addition, recent findings have
indicated that cardiomyocyte proliferation can be modulated
during development by ANP or BNP [141]. Furthermore,
it is noticeable that plasma BNP in humans is high at
birth, progressively declining thereafter, to stabilize at around
ten years of age to the levels found in adults [142, 143].
Taken together, these observations suggest that BNP may
play important functions as a regulator of cardiomyocyte
differentiation and proliferation in the developing embryo. In
line with this hypothesis, it has been reported that embryonic
stem cells express high levels of BNP which are essential for
their proliferation and differentiation [126].
These results raise the possibility that BNP might also
be involved in the process of cellular regeneration in the
adult. A role of BNP was indeed reported by Kuhn et al.
in the process of angiogenesis following skeletal muscle
ischemia [127]. In this study, secretion of BNP by vascular
satellite cells was found to activate, in a paracrine manner,
the regeneration of the adjacent endothelium. So, what about
cardiac regeneration?
3.2.5. Role of BNP in Cardiac Regeneration. We addressed
the role of BNP in cardiac regeneration in our laboratory by
performing a series of experiments evaluating the relation-
ships between CPCs and BNP both in vitro and in vivo. The
first clue for an involvement of BNP in CPC proliferation
and differentiation comes from our data indicating the age-
dependence of BNP expression in the heart. As shown in
Figure 3(a) and already published [117], more cardiac cells
stained positive for BNP in mouse neonatal compared to
adult hearts: in the neonatal hearts 65±4%of the cardiac cells
were positive for the BNP’s staining compared to the adult
hearts (41 ± 1% of the cells) (Figure 3(a)). BNP staining is
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Figure 3: Heart expression of BNP is age-dependent and cell specific. (a) Representative microscopy pictures of neonatal and adult hearts
stained for BNP (in red) and DAPI (nuclei in blue). High magnification of positive cells in top right inserts. The scale bars represent 100 𝜇m.
(b) mRNA expression of BNP using quantitative PCR, in non-myocyte cells (NMCs) (blue) and cardiomyocytes (red). Results expressed as
fold-increase above the levels in NMCs. 𝑛 = 7 cardiomyocyte samples compared to 9 NMC samples. Data are means ± SEM, ∗𝑃 < 0.05.
(c) Determination of BNP protein levels in neonatal and adult hearts by western blot analysis. BNP protein expression with representative
western blot and quantification relative to tubulin, expressed as fold changes relative to the average level of neonatal hearts. Data are means
± SEM, ∗𝑃 < 0.05. a.u.: arbitrary unit.
localized around the nucleus in neonatal and adult cardiac
cells (inserts Figure 3(a)). By western blot analysis, several
isoforms were detected as our antibody is able to recognize
all proBNP isoforms as well as the active form of the BNP
(C-terminal peptide). The high molecular weight forms (24
and 17 kDa) correspond to the glycosylated proBNP isoform
(Figure 3(c)) as previously described [144, 145], whereas the
proBNP (12-13 kDa) was only detected in the neonatal hearts.
According to previous reports, the active BNP form (10 kDa)
is not detectable in neonatal or adult hearts by western
blot analysis [121, 144]. All proBNP isoforms were more
abundant in neonatal than in adult hearts (see quantification
in Figure 3(c)).
In the neonatal hearts, BNP mRNA is 300-fold more
abundant in the cardiomyocytes than in the non-myocyte
cells (NMCs), suggesting that the mean source of BNP in the
neonatal hearts is the cardiomyocytes (Figure 3(b)). This is
also true in the adult hearts: BNP mRNA expressed by the
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NMCs represented less than 0.05% of the mRNA coding for
BNP detected in the adult hearts (data not shown).
Further indications for a role of BNP in cardiac growth
and/or regeneration come from our finding that CPCs
identified in vivo in neonatal and adult hearts express
the BNP receptors, NPR-A, and/or NPR-B [117]. Although
BNP can share these receptors with other members of
the natriuretic peptide family (NPR-A can also bind the
atrial natriuretic peptide and NPR-B the C-type related
natriuretic peptide) [120], these data strongly support that
CPCs are able to respond to BNP. We then found that
treatment with exogenous BNP increased the number of
newly formed cardiomyocytes and of proliferating CPCs in
neonatal and adult unmanipulated mice. Our next finding
was that BNP injection in mice exposed to MI resulted
in an increased number of CPCs and of cardiomyocytes
expressing Nkx2.5, and this was associated with reduced
cardiac remodeling and improved contractile function after
MI [117]. Overall, our findings provided strong evidence in
support of a crucial role for BNP in controlling proliferation
and differentiation of CPCs after birth, therefore suggesting
that the administration of BNP might be a useful therapeutic
approach to promoting regeneration of the infarcted heart
[117].
Furthermore, we observed also that CPCs (identified
as being small laminin positive cells expressing Nkx2.5
(Nkx2.5+ cells) or Sca-1+/Nkx2.5+ cells or c-kit+/Nkx2.5+
cells) stained also positive for BNP, suggesting that CPCs
are also able to synthesize BNP (Figure 4). CPCs could
thus secrete BNP in an autocrine manner to control their
proliferation and differentiation into cardiomyocytes.
3.2.6. Mechanisms of BNP Actions in the Heart: Studies in
NPR-A KO and NPR-B Deficient Mice. The demonstration
that BNP has potent effects on CPCs prompted us to search
for the cellular BNP receptor implicated in such actions.
It is known that BNP can bind to two receptors, namely,
NPR-A and NPR-B, and we therefore undertook a series of
experiments using mice deficient for one or the other of
these receptors [120]. We first noticed that the percentage
of NPR-A KO mice at birth was lower than expected from
the Mendelian frequency (19% instead of 25%), suggesting
that NPR-A KO embryos die during embryogenesis, as
already reported by others [146]. Furthermore, a high rate
of mortality occurs in NPR-A KO pups between day 1 and
day 10 (at day 10, only 8% of the surviving pups are NPR-A
KOmice, instead of the expected 25%, Figure 5). In contrast,
NPR-B-deficient pups are born at the expected Mendelian
frequency but die within 3 days after birth (Figure 5). These
observations implicate BNP receptors in biological processes
critical to survival during embryogenesis and early after natal
life. This assumption would be consistent with previously
reported roles of BNP and BNP receptors in embryonic
stem (ES) cells, as reported by Abdelalim and Tooyama [126,
147]. These authors proposed that NPR-A contributed to the
self-renewal and maintenance of pluripotency of ES cells,
whereas NPR-B was instead involved in their proliferation
[126, 147].
Cardiac defects could be the cause of the premature
death of NPR-A KO pups. Indeed, at 15.5 days of gestation,
NPR-A KO embryos display a cardiomegaly without fibrosis,
as well as dysregulated expression of the Cx43 protein,
which could affect cardiac contractility [146]. At adulthood,
NPR-A KOmice develop salt-resistant hypertension together
with cardiac hypertrophy, which is out of proportion with
respect to the increase in blood pressure, implying direct
antihypertrophic actions of NPR-A in the heart [146, 148–
150]. Concerning the NPR-B system, previous reports indi-
cated impaired endochondral ossification, gastrointestinal
tract disorders, and defects of the reproductive organs
in NPR-B-deficient mice [151–155], but there is no result
on their cardiac phenotype. Some information has been
obtained by the use of transgenic rats expressing a dominant-
negative mutant of NPR-B, which display a progressive,
blood pressure-independent cardiac hypertrophy, which is
further enhanced following the induction of congestive heart
failure by volume overload [156]. Therefore, these results
support that NPR-B is also involved in the control of cardiac
growth.
In our own studies, we recently demonstrated that both
receptors control the fate of the cardiac precursor cells
in vitro [117]. First, we demonstrated that CPCs exist in
neonatal hearts of NPR-A KO and NPR-B-deficient mice.
Secondly, we showed that BNP stimulates CPC prolifera-
tion in vitro via its binding to NPR-A (Figure 6). Thirdly,
we established that BNP stimulates CPC differentiation
into cardiomyocytes via binding to NPR-B in cell culture.
Whether a defect in the proliferation and/or differentiation
of CPCs contributes to cardiac defects and premature death
in NPR-A KO and NPR-B-deficient mice remains now to be
explored.
3.2.7. The Use of BNP in the Clinic. The first clinical tri-
als with recombinant human BNP (Nesiritide) in patients
with acute heart failure reported positive hemodynamic and
clinical effects, leading to the common use of this drug
in the therapeutic arsenal of both acute and chronic heart
failure. Later studies, however, raised several safety concerns
about Nesiritide, the drug being possibly associated with
greater risk of renal failure and higher mortality, which
resulted in significant reduction in its clinical use [157,
158]. Nevertheless, more recent clinical studies reported that
low doses of Nesiritide, in particular when administered
via subcutaneous route, induced hemodynamic and clinical
improvements without increasing nephrotoxicity or the rate
of death, thus reopening the debate about the usefulness
of BNP therapy in patients with heart failure [157, 159–
162]. In addition, a recent meta-analysis on the use of
natriuretic peptides (ANP/BNP) in patients with acute MI
suggested that this treatment might protect left ventric-
ular function [163] and a large-scale randomized clinical
trial (BELIEVE II) has been recently initiated to evaluate
such cardioprotective effects of low dose BNP during AMI
[164].
Finally, it is particularly noteworthy that an inhibitor
of neprilysin has been very recently shown to promote
significant benefits in patients with chronic heart failure,
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Figure 4: Cardiac precursor cells express BNP in neonatal and adult murine hearts. Cardiac precursor cells were defined as small Nkx2.5+
cells or c-kit+/Nkx2.5+ cells or Sca-1+/Nkx2.5+cells. Photomicrographs of neonatal or adult heart sections stained for BNP and DAPI (Nuclei)
associated with staining for either Nkx2.5 and laminin (a), Nkx2.5 and c-kit (b), or Nkx2.5 and Sca-1 (c). Scale bars represent 80𝜇m for the
pictures in (a) and 10 𝜇m for the pictures in (b) and (c). Yellow arrows depict cells which are considered as being CPCs expressing BNP.
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when compared to angiotensin-converting enzyme inhibi-
tion (PARADIGM-HF trial) [165, 166]. Neprilysin (NEP)
is an endopeptidase able to degrade several factors such
as the natriuretic peptides (ANP, CNP, and BNP), but also
angiotensin II, bradykinin, or endothelin-1. In the heart, NEP
is expressed on the membrane of endothelial cells, vascular
smooth muscle cells, fibroblasts, and cardiomyocytes and
treatments of rats or rabbits with NEP inhibitors increase
the blood level of BNP [167, 168]. However, NEP treatment
in animal and humans has also shown to increase the blood
level of angiotensin II. That is why NEP inhibitors are used
with inhibitors of angiotensin-converting enzyme (ACE)
such as the omapatrilat or with blocker of the angiotensin
receptor, such as the LCZ696. Omapatrilat has been shown
in infarctedmice to increase cardiac function and to decrease
the fibrosis and the cardiomyocyte hypertrophy when com-
pared to untreated infarctedmice [169]. However, in humans,
omapatrilat was associated with development of angioedema
and was not approved by the Food and Drug Administration.
Thus great hope focuses now on LCZ696. In infarcted rats,
LCZ696 treatment decreases the myocardial fibrosis and the
cardiomyocyte hypertrophy and thus increases the ejection
fraction of the treated rats compared to untreated one
[170].
In patients, the mechanisms of LCZ696 leading to
reduced death and rehospitalization are not yet elucidated
[171]. However, increasing BNP signaling appears therefore as
ameaningful and helpful strategy in patients withmyocardial
infarction and/or heart failure. Although it is likely that
systemic vasodilation and natriuresis are key mechanisms
underlying the beneficial effects of natriuretic peptides in the
aforementioned studies, the positive effects of BNPon cardiac
regenerative processes, as highlighted in our recent work,
could also play an important role, an issue which should
be critically addressed in ongoing clinical and experimental
studies.
4. Conclusion-Future Perspectives
Therapy of cardiovascular diseases represents a major pub-
lic health challenge. Primary prevention, including lifestyle
modification and treatment of traditional cardiovascular risk
factors, together with secondary and tertiary prevention by
multidrug treatment, has been the mainstay of such therapy
for decades. In recent years, novel approaches based upon
the regeneration of the injured heart have been developed,
holding the promise not only to relieve, but also to directly
repair the damaged heart. The observation that stem cells
isolated fromdifferent organs retain the ability to differentiate
into mature adult beating cardiomyocytes promoted strong
impetus to launch a series of clinical trials evaluating the
therapeutic potential of cellular regenerative therapies in
cardiac diseases. Lessons learned from these studies indicated
that although such approaches appeared generally safe, their
efficacy remained globally limited. Factors such as the nature
of the injected cells, their number, and the route and timing
of their administration emerged as critical issues which will
need to be addressed in future studies to improve such
efficacy. Furthermore, it has become obvious that cardiac
regeneration involves complex interplays between different
cell subsets of both cardiac and extracardiac (blood or bone
marrow) origin, which cannot be mimicked by the one and
only administration of cardiac precursor cells. A potential
strategy to circumvent, at least partly, the limitations of
cellular regenerative therapies could rely on the stimulation
of the heart’s natural ability to induce its own regeneration
by pharmacological approaches. Indeed, pharmacological
compounds could target not only the cellular precursors
but also other cells involved in the regenerative and healing
process, for instance, the fibroblasts, the endothelial cells, and
the infiltrating cells, such as the different monocyte subsets.
Treatment with exogenous brain natriuretic peptide is an
example of such strategy, as demonstrated experimentally
by its ability to induce “endogenous” cardiac regeneration.
Future studies should endeavor to discover novel molecules
able to stimulate such genuine capacity of the heart to regen-
erate, which would represent an indisputable breakthrough
in the fight against cardiovascular diseases.
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